Regulatory News
Tuesday, November 29, 2016
BRIEF-Kempharm receives clearance from FDA to initiate clinical program for KP201/IR
* Kempharm receives clearance from FDA to initiate clinical
program for KP201/IR, a single-entity benzhydrocodone HCL
immediate release abuse-deterrent prodrug for the treatment of
acute pain
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment